Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.34 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.34 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601082 | 0.82 | DDB1 (0.44) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23590046 | 0.81 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL10074225 | 0.77 | DDB1 (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL442296 | 0.75 | CRBN (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL410243 | 0.75 | CRBN (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL7284377 | 0.75 | CRBN (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL410700 | 0.75 | CRBN (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL14377303 | 0.72 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15930060 | 0.72 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL13464214 | 0.71 | DDB1 (0.43) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846800-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | DDB1 104/4885CRBN 328/4885IKZF3 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.